Pfizer announced that inclacumab, a sickle cell disease drug candidate acquired from Global Blood Therapeutics, failed to meet its primary endpoint in a Phase 3 clinical study. The candidate did not significantly reduce vaso-occlusive crisis rates compared to placebo, representing a setback for Pfizer’s sickle cell portfolio amid other challenges such as market withdrawal of related agents. This failure highlights the ongoing difficulties in developing effective treatments for sickle cell disease and poses strategic challenges for Pfizer.